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Few things are harder to put up with than the annoyance of 
a good example. - Mark Twain 
Natural killer (NK) cells are a subpopulation of lympho- 
cytes that can mediate the lysis of certain tumor ceils, 
virus-infected cells, and normal hematopoietic cells (Trin- 
chieri, 1989). Yet, little has been known regarding the re- 
ceptor-initiated mechanisms regulating these activations. 
In fact, several counterintuitive observations have dogged 
investigators interested in their biology. For example, why 
do NK cells from Fl hybrid mice reject bone marrow cells 
derived from either parental strain (hybrid resistance)? 
More broadly, why do NKcells preferentially kill target cells 
lacking major histocompatibility complex (MHC) class I 
molecules? This review focuses on recent investigations 
that have provided new insights into the mechanisms regu- 
lating these processes. Specifically, analyses have identi- 
fied novel MHC-recognizing receptors on clonal populations 
of NK cells, and it appears that the negative regulatory sig- 
nals generated after these receptors bind their ligands 
critically influences their cellular functions. 
Hybrid Resistance and the “Missing Selr 
Decades ago, investigators clearly established that an Fl 
hybrid between two H-2 disparate murine parents rejects 
bone marrow cell grafts from either parent (Snell, 1958; 
Cudkowicz and Stimpfling, 1984; Yu et al., 1992). This 
hybrid resistance was inconsistent with dominantly inher- 
ited susceptibility to T cell-mediated graft rejection, and 
novel models to explain this discrepancy were generated. 
Subsequent studies showed that NK cells mediated this 
hybrid resistance (Kiessling et al., 1977) and, moregener- 
ally, that NK cells can eliminate cells because critical MHC 
class I molecules are absent from the cell surface of the 
target (Ljunggren and Karre, 1990). This included clear in 
vivo demonstrations that NK cells can mediate rejection 
of MHC class l-deficient bone marrow cells (e.g., f32- 
microglobulin-deficient bone marrow cells rejected in nor- 
mal MHC-expressing mice) (Bix et al., 1991; Hoglund et 
al., 1991) and MHC class l-deficient tumor cells (e.g., H-2 
class l-deficient variant lymphomas rejected in syngeneic 
mice) (Karre et al., 1988). Even mice expressing an MHC 
class I transgene could reject tumor cells identical in MHC 
expression except for the absence of the transgene (Hog- 
lund et al., 1988). The inverse correlation between the 
susceptibility of target cells to NK cell-mediated cytotoxic- 
ity and the expression of self-class I led to a proposed 
model in which MHC recognition by novel receptors on 
NK cells results in a negative signal that down-modulates 
NK cell killing of class I+ targets (effector inhibition model) 
(Ljunggren and Karre, 1990). 
MHCRecognlzing Receptors: C-Type Lectln Versus 
lmmunoglobulln Superfamily Structure 
Recent reports suggest two very different families of re- 
ceptors that can inhibit NKcell activation after MHC recog- 
nition (Figure 1). The Ly-49 family of murine receptors are 
type II integral membrane proteins with homology to the 
C-type lectin superfamily (Yokoyama et al., 1989). Mem- 
bers of this superfamily can bind carbohydrate residues 
in a CaWependent manner, and specific members of the 
Ly-49 family appear to recognize carbohydrate residues 
in their binding interactions with MHC class I molecules 
(Daniels et al., 1994). Although these lectin-like molecules 
have specificities for carbohydrates, the potential role for 
amino acid recognition in determining their binding speci- 
ficity remains unknown. Among the currently identified Ly- 
49 members are Ly49A (reacts with H-2Dd and H-2Dk 
(Karlhofer et al., 1992) Ly49C (also termed 5E8; reacts 
with H-2q (Bennett et al., 1995) and Ly49G2 (also termed 
LGL-1; reacts with H-2Dd and H-2Ld) (Mason et al., 1995). 
Revealing studies by Yokoyama (1995) and colleagues 
show that the interaction of Ly49 family members, such 
as Ly49A, with MHC class I such as H-2Dd or H-2Dk can 
deliver a negative signal to NK cells. They have shown 
that Ly49A+ NK cells, unlike Ly49- cells, are unable to 
lyse targets expressing H-2Dd or H-2Dk; anti-Ly49A or anti- 
class I al/a2 domain antibodies restore lysis; and Ly49+ 
cells bind to purified Dd or Dk molecules. Importantly, for 
any given mouse, there are subpopulations of NK cells 
that differ in their expression of Ly49 family members and 
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Figure I. Inhibition of Lymphocyte Activation after MHC Class I Rec- 
ognition 
Schematic diagram of receptors expressed on either NK cells or T 
cells that, after binding to their ligands, regulate their cellular functions. 
Adhesion molecules (e.g., LFA-1, ICAM-1) are critical for effector- 
target conjugate formation. Triggering receptors (e.g., Fc$tlll and 
NKR-Pl on NKcellsandTcell receptoronTcells)cangeneratesecond 
messengers that initiate cellular cytotoxicity and gene transcription. 
Murine Ly-49 (C-type lectin) or human p59 (immunoglobulin super- 




a single NKcell can express more than one Ly49 member. 
Recent data suggests that differential expression of Ly49 
members can account for the phenomenon of hybrid resis- 
tance without invoking the existence of recessively inher- 
ited histocompatibility antigens (Bennett et al., 1995). At- 
tempts performed to date have not identified human 
homologues to murine Ly-49. Human CD94 (previously 
called Kp43) is a member of the C-type lectin superfamily 
and its ligation can inhibit NK cell activation, but its ability 
to recognize MHC is controversial (Yokoyama, 1995; Mor- 
etta et al., 1994a). 
Surprisingly, the MHC-recognizing receptors identified 
to date on human NK cells have a fundamentally different 
structure. Recent reports show that specific receptors on 
NK cells associated with HLA-C and HLA-B recognition 
(members of the p58 family) have two or three immuno- 
globulin superfamily domains in their extracellular region 
and lack C-lectin homology (Colonna and Samaridis, 1995; 
Wagtmann et al., 1995). The cytoplasmic regions contain 
modified antigen recognition activation motifs (ARAM) with 
extended spacing between the two YXXL motifs (D/E&D/ 
EXXYXXLX~YXXL). Comparisons of NK-specific comple- 
mentary DNA transcripts revealed approximately 80% 
identity among family members, with divergent amino 
acids dispersed throughout the extracellular, transmem- 
brane, and cytoplasmic domains and variable length cyto- 
plasmic tails. The observed polymorphisms raise ques- 
tions as to the structure-function relationships, which 
account for differences in MHC recognition and differ- 
ences in regulatory functions (i.e., inhibition versus activa- 
tion). It is firmly established that there are clonal differ- 
ences within an individual in the capability of human NK 
cells to recognize MHC class I; clones differ in their expres- 
sion of p58 family members; specific p58 molecules corre- 
late with HLA haplotype specificity; single clones can ex- 
press several MHC-recognizing receptors with different 
specificities; and NK-resistant targets bearing MHC on 
their surface can become susceptible to NK cell-mediated 
killing if the targets are preincubated with anti-class I 
monoclonal antibody or the NKcellsare preincubated with 
specific anti-p58 monoclonal antibodies (Colonna and Sa- 
maridis, 1995; Wagtmann et al., 1995; Litwin et al., 1993; 
Moretta et al., 1994b). Thus, the clonotypic distribution of 
these MHC-recognizing receptors appears to define their 
MHC haplotype reactivity and repertoire. Attempts per- 
formed to date have not identified murine homologs to the 
p58 molecules. 
Role of Peptide in NK Cell Recognition of MHC 
Multiple investigations have focused on the ability of class 
I molecules to present antigen-derived peptides to T lym- 
phocytes. However, as emerging evidence has shown the 
ability of receptors on NK cells also to recognize MHC, the 
central issue as to the role of peptide remains unresolved. 
Clearly, peptide could be important simply to bind to class 
I molecules and stabilize their expression at the cell sur- 
face, resulting in broad protection from NK cell-mediated 
killing. Alternatively, only certain key peptides, when 
bound by MHC, might be able to be recognized by recep- 
tors on NK cells, and thus confer protection. This latter 
mechanism would imply that the substitution of a nonpro- 
tective peptide epitope (e.g., a viral peptide) for a protec- 
tive peptide could result in enhanced susceptibility to NK 
cell-mediated cytotoxicity. Therefore, without reducing the 
amount of MHC class I expression on a cell, qualitative 
changes in peptide-MHC complexes on the cell surface 
could critically influence susceptibility of the cell to killing. 
Correa and Raulet (1995) found that all of the H-2Dd- 
binding peptides they tested could inhibit murine NK cells 
expressing Ly-49 receptors for this class I molecule. Spe- 
cifically, by loading the mostly empty H-2Dd in cells defi- 
cient in peptide transporter molecules, resistance to killing 
was obtained in a dose-dependent manner. The fact that 
all the Dd-binding peptides employed conferred protection 
suggested little or no peptide discrimination in this system. 
In contrast, studies looking at human NK cell recognition 
of HLA class I molecules have suggested that peptides 
can differentially influence susceptibility (Storkus et al., 
1992; Malnati et al., 1995). The specific peptide, the struc- 
ture of the peptide-binding cleft, and the clonotypic expres- 
sion of MHC-recognizing receptors all influenced this sus- 
ceptibility. This fine discrimination would be consistent 
with the suggestion that qualitative changes in the target 
structures of virus-infected targets could play a role in the 
NK cell-mediated killing of virus-infected cells (Kaufman 
et al., 1992). It remains to be determined whether the diver- 
gent results noted above represent differences between 
murine and human MHC recognition (e.g., mediated by 
Ly-49 versus ~58) or in the experimental models em- 
ployed. 
NK Cell Education and Learning Self 
Although most of the experimental systems have focused 
on the ability of alloantigens to modulate NK cell activation, 
it is teleologically appealing to expect NK cells to be able 
to survey tissues for expression of self-MHC complexed 
with peptide. In fact, this has clearly been shown to be 
the case for murine NK cell-mediated rejection of class 
l-deficient bone marrow grafts (Bix et al., 1991; Hoglund 
et al., 1991) class l-deficient tumor cells (Karre et al., 
1986) malignant cells lacking an MHC class I transgene 
(Hoglund et al., 1968) for hybrid resistance (Vu et al., 
1992), and for human NK cells inhibited by self-MHC 
(Litwin et al., 1993). Interestingly, the ability to recognize 
self-class I appears to be retained even when the level 
of self-reactive receptors is significantly down-modulated 
(Karlhofer et al., 1994). Selection of the MHC-reactive rep- 
ertoire must clearly occurduring NKcell development. For 
example, although NK cells from class l-expressing mice 
can reject class l-deficient bone marrow, NK cells in 62- 
microglobulin-deficient mice do not reject their own class 
l-deficient cells (Bix et al., 1991; Hoglund et al., 1991). It 
would also seem likely that NK clones in class I-express- 
ing individuals that do not have a receptor for at least 
one autologous class I haplotype would be eliminated or 
become anergic during differentiation to prevent autoreac- 
tive NK cells in vivo. If NK cells are also able to recognize 
differentially the peptides complexed to MHC, this implies 
another level of education and selection by as yet unidenti- 
fied mechanisms. 
$finireview 
inhibitory Versus Stimuiatory Effects of MHC 
Recognition (Functional Ambivalence) 
The major emphasis to date has been on the profound 
inhibitory effect on NK cell activation that can occur after 
ligation of the MHC-recognizing receptors. However, 
emerging data suggest that cross-linking of some of these 
same receptors (e.g., certain Ly49 family members, p58 
members, rat MHC-recognizing receptors, and CD94) on 
separate clonal populations of NK cells can activate gran- 
ule exocytosis, cell-mediated cytotoxicity, and lymphokine 
production (Mason et al., 1991; Melero et al., 1994; Rol- 
stad et al., 1994; Perez-Villar et al., 1995). For example, 
the cytolytic activity of some clonal populations of human 
NK cells is inhibited after CD94 (Kp43) ligations, whereas 
cross-linking CD94 on separate clonal populations can be 
strikingly activating (Perez-Villar et al., 1995). Although it 
remains unclear as to the mechanism for these differential 
effects, multiple heterogeneous aspects to these mole- 
cules could potentially influence these processes. Clonal 
populations differ dramatically in their degree of receptor 
expression, with, for example, cells expressing high levels 
of CD94 being inhibited after receptor ligation and cells 
expressing low-to-intermediate levels being activated. In 
addition, although serologic identification of certain mole- 
cules might suggest identity, differences in primary amino 
acid sequences and posttranslational modifications (e.g., 
glycosylation) appear likely. Finally, the recent molecular 
characterizations of the p58 family of receptors suggest 
that the cytoplasmic tails differ significantly in composition 
and length, thus providing a potential structural foundation 
for differential signaling. It should be emphasized that 
most of the studies to date showing functional ambiva- 
lence have been done using receptor-specific monoclonal 
antibodies for cross-linking, and that future studies will 
need to assess the ability of MHC class I molecules to 
affect the activating process similarly. 
Signaling Events in NK Cells Recognizing 
MHC Class I 
Analyses of negative regulation after MHC recognition 
have been complicated by the heterogeneous nature of 
these interactions. First, there are several familiesof MHC- 
recognizing receptors and within each family there are 
multiple members. Different receptors recognize different 
subsets of MHC class I molecules, and a given clonal 
population can express multiple MHC-recognizing recep- 
tors. In addition, depending on the NK clone, MHC recogni- 
tion can be alternatively activating or inhibitory. Therefore, 
depending on the variety of MHC-recognizing molecules 
on a given subpopulation of NK cells and on the multiple 
types of class I on a given target, the nature of the effector- 
target interaction can be quite complex. In the context of 
all of this heterogeneity, it has been observed that most 
cloned human NK cell lines are only partially inhibited in 
their killing of MHC-bearing targets, and it has been diffi- 
cult to identify discernible correlations between NK cell 
recognition of MHC and a reduction in early signaling 
events in NK cells (Kaufman et al., 1993). However, recent 
analyses have identified experimental models in which 
NK cell-mediated cytotoxicity was fully inhibited by the 
recognition of specific MHC class I molecules (Kaufman 
et al., 1995). These evaluations suggested that the MHC 
recognition could inhibit key critical signaling events. Spe- 
cifically, whereas NKcells binding toclass l-bearing target 
cells could initiate some degree of proximal protein tyro- 
sine kinase activation, the generation of pharmacologi- 
cally active phosphoinositide-derived second messengers 
was potently inhibited. In separate analyses, p58 family 
members have been shown to be physically associated 
with CDSC, FcsFti~, and ~58~ (Sottino et al., 1994). This 
information, together with the new molecular identifica- 
tionsof specific MHC-recognizing receptors and the identi- 
fication of ARAM motifs in their cytoplasmic tails, should 
provide the foundation for identifying specific signaling 
events related to negative versus positive regulation. 
T Ceils Expressing inhlbitory 
MHC-Recognizing Receptors 
Most models of antigen-driven T cell activation have fo- 
cused on the ability of the MHC-peptide complex to inter- 
act with the T cell receptor to stimulate cellular responses. 
However, recent reports suggest that subpopulations of 
T lymphocytes can also express the MHC-recognizing re- 
ceptors described more broadly for NK ceils (Mingari et 
al., 1995; Phillips et al., 1995). These receptors, when 
ligated by MHC, appear to be able to inhibit potently cyto- 
toxic T lymphocyte-mediated killing and lymphokine pro- 
duction. A high proportion of activated T cells seem to 
bear one or more forms of these MHC-recognizing recep 
tors and the class I recognition can effectively inhibit their 
ability to kill otherwise susceptible targets. This suggests 
the potential for both positive and negative regulatory influ- 
ences for a given T cell after MHC recognition. The final 
integrated response may well depend on a myriad of cellu- 
lar parameters, including levels of receptor expression, 
receptor specificity, affinity of receptors for ligand, et cet- 
era. It remains to be determined whether pathologic condi- 
tions of unresponsiveness or autoimmunity are influenced 
by an inappropriate balance of these counteracting regula- 
tory mechanisms. 
Concluding Remarks 
Although it has been known for a couple of decades that 
NK cells can mediate lysis of certain tumor cells and virus- 
infected cells without prior sensitization, the molecular ba- 
sisfor recognition of susceptible targets remained unclear. 
Interactions of triggering receptors (e.g., NKR-Pl) on NK 
cells with specific target cell epitopes (e.g., carbohydrate 
moieties) can contribute to this process (Bezouska et al., 
1994). But recent information also suggests that the pres- 
ence or absence of inhibitory signals can critically influ- 
ence this killing mechanism. Whereas natural cytotoxicity 
has been often described as MHC unrestricted, it is now 
clear that the interaction of clonally expressed MHC- 
recognizing receptors with specific MHC-peptide com- 
plexes on target cells can provide a key regulatory function. 
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